Rep. Gilbert Ray Cisneros, Jr. Buys AstraZeneca PLC (NASDAQ:AZN) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

AstraZeneca Trading Down 2.4%

NASDAQ AZN traded down $2.35 on Thursday, hitting $93.99. The company’s stock had a trading volume of 9,146,390 shares, compared to its average volume of 6,975,408. The company’s 50-day moving average is $91.12 and its 200 day moving average is $82.50. The firm has a market cap of $291.51 billion, a PE ratio of 31.23, a PEG ratio of 1.56 and a beta of 0.34. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $96.51. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The company had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.08 earnings per share. As a group, analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Institutional Trading of AstraZeneca

Several large investors have recently made changes to their positions in AZN. Binnacle Investments Inc grew its stake in AstraZeneca by 21.8% in the third quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after acquiring an additional 118 shares during the period. Chapin Davis Inc. lifted its holdings in shares of AstraZeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after purchasing an additional 120 shares in the last quarter. 44 Wealth Management LLC grew its position in AstraZeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after purchasing an additional 124 shares during the period. CoreCap Advisors LLC grew its position in AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after purchasing an additional 125 shares during the period. Finally, Highline Wealth Partners LLC lifted its stake in shares of AstraZeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after buying an additional 129 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Guggenheim restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating on the stock. Wall Street Zen upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Finally, Cowen reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.